Cell-Free DNA—A Marker to Predict Ischemic Brain Damage in a Rat Stroke Experimental Model

Boyko, Matthew; Ohayon, Sharon; Goldsmith, Tomer; Douvdevani, Amos; Gruenbaum, Benjamin F.; Melamed, Israel; Knyazer, Boris; Shapira, Yoram; Teichberg, Vivian I.; Elir, Adina; Klein, Moti; Zlotnik, Alexander

doi:10.1097/ana.0b013e31821b536a

Cited by 30 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CfDNA has been detected in plasma, serum, urine, and other body fluids from healthy subjects as well as in patients 7. Circulating cfDNA has now been shown to be useful in the diagnosis or monitoring of diseases such as trauma stroke,8 myocardial infarction,9 and tumor 10. In this prospective study, we provided important evidence of the association between serum cfDNA and progression of DKD.…”

Section: Discussionmentioning

confidence: 77%

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Luo

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

AimsCell-free DNA (cfDNA) is associated with diabetes and cardiovascular diseases. Our study was to evaluate whether serum cfDNA could predict the progression of diabetic kidney disease (DKD).MethodsIn this prospective study, a total of 160 patients with DKD were enrolled, and the kidney function was followed up by measurement of estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) for three consecutive years. At baseline, concentrations of serum cfDNA were measured. DKD progression was defined as two-continuous decrease in eGFR and changes of UACR from less than 300 mg/g at baseline to higher than 300 mg/g at last follow-up. Regression models were used to analyze associations of serum cfDNA with the DKD progression.ResultsIn total, 131 patients finished all the follow-up visits. At the end of the study, 64 patients showed decreased eGFR and 29 patients had changes of UACR from less than 300 mg/g at baseline to higher than 300 mg/g at follow-up. At baseline, the progression group had higher serum cfDNA levels than the non-progression group (960.49 (816.53, 1073.65) ng/mL vs 824.51 (701.34, 987.06) ng/mL, p=0.014). Serum cfDNA levels were significantly negatively associated with the 1.5-year eGFR change (r=−0.219 p=0.009) and 3-year eGFR change (r=−0.181, p=0.043). Multivariate logistic analyses showed that after adjustment of age, gender, body mass index, fast plasma glucose, smoking, triglycerides, total cholesterol, duration of diabetes, systolic blood pressure, diabetic retinopathy, eGFR, high sensitivity C-reactive protein, angiotensin receptor blocker/ACE inhibitor usage, with the increase of one SD of serum cfDNA levels, the risk of DKD progression increased by 2.4 times (OR, 2.46; 95% CI 1.84 to 4.89).ConclusionSerum cfDNA is closely associated with DKD, and it might be a predictor of DKD progression in patients with type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 77%

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Luo

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…In comparison, Chiu et al state the QPCR method as taking between 90 and 180 minutes to perform [7]. In recent studies we found that CFD levels measured using our method efficiently reflect the severity of disease and the dimensions of damaged tissue in human and experimental animal models [12–15]. …”

Section: Discussionmentioning

confidence: 92%

Admission Cell Free DNA as a Prognostic Factor in Burns: Quantification by Use of a Direct Rapid Fluorometric Technique

Shoham

Krieger

Perry

et al. 2014

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background. Despite great advances in the treatment of burn patients, useful prognostic markers are sparse. During the past years there has been increasing interest in circulating plasma cell free DNA as a potential marker for tissue injury. We have developed a rapid direct fluorescent assay for cell free DNA quantification that allows obtaining accurate, fast, and inexpensive measurements. Objective. To use this technique for measuring plasma cell free DNA levels in burn patients and to further explore the use of cell free DNA as a potential marker of patient outcome in burns. Methods. Cell free DNA levels obtained from 14 burn victims within 6 hours of injury and 14 healthy controls were quantified by a direct rapid fluorometric assay. Results. Patient admission cell free DNA levels were significantly elevated compared with that of controls (1797 ± 1523 ng/mL versus 374 ± 245 ng/mL, P = 0.004). There are statistically significant correlations between cell free DNA admission levels and burn degree (Spearman's correlation = 0.78, P = 0.001), total body surface area (Spearman's correlation = 0.61, P = 0.02), and total burn volume (Spearman's correlation = 0.64, P = 0.014). Conclusions. Admission cell free DNA levels can serve as a prognostic factor in burns and future routine use can be made possible by use of our direct rapid fluorometric assay.

show abstract

“…In particular, the rapid clearance of ecDNA from the circulation is considered to be of potential interest for disease progression monitoring [13]. Although most of the studies focus on cancer, tissue damage in non-malignant conditions was found to be associated with high concentrations of ecDNA, namely stroke, myocardial infarction, and burns [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Plasma Concentrations of Extracellular DNA in Acute Kidney Injury

et al. 2020

View full text Add to dashboard Cite

Current diagnostic methods of acute kidney injury (AKI) have limited sensitivity and specificity. Tissue injury has been linked to an increase in the concentrations of extracellular DNA (ecDNA) in plasma. A rapid turnover of ecDNA in the circulation makes it a potential marker with high sensitivity. This study aimed to analyze the concentration of ecDNA in plasma in animal models of AKI. Three different fractions of ecDNA were measured—total ecDNA was assessed fluorometrically, while nuclear ecDNA (ncDNA) and mitochondrial DNA (mtDNA) were analyzed using quantitative real-time PCR. AKI was induced using four different murine models of AKI-bilateral ureteral obstruction (BUO), glycerol-induced AKI (GLY), ischemia–reperfusion injury (IRI) and bilateral nephrectomy (BNx). Total ecDNA was significantly higher in BUO (p < 0.05) and GLY (p < 0.05) compared to the respective control groups. ncDNA was significantly higher in BUO (p < 0.05) compared to SHAM. No significant differences in the concentrations of mtDNA were found between the groups. The plasma concentrations of different fractions of ecDNA are dependent on the mechanism of induction of AKI and warrant further investigation as potential surrogate markers of AKI.

show abstract

Cell-Free DNA—A Marker to Predict Ischemic Brain Damage in a Rat Stroke Experimental Model

Cited by 30 publications

References 43 publications

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Admission Cell Free DNA as a Prognostic Factor in Burns: Quantification by Use of a Direct Rapid Fluorometric Technique

Plasma Concentrations of Extracellular DNA in Acute Kidney Injury

Contact Info

Product

Resources

About